Ile-Pro-Pro cas: 26001-32-1

CAS NO: 26001-32-1
Ile-Pro-Pro
Chemical Name: H-ILE-PRO-PRO-OH
Molecular Formula: C16H27N3O4
Formula Weight: 325.4
CAS No.: 26001-32-1
Description Review
Description

Ile-Pro-Pro, also known as IPP, is a tripeptide composed of isoleucine, proline, and proline. It is found naturally in foods such as milk and soybeans and has been shown to have potential health benefits, including its ability to lower blood pressure and improve endothelial function. In this article, we will discuss the chemical and physical properties of Ile-Pro-Pro, its health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.

Chemical Name L-isoleucyl-L-prolyl-L-proline

Molecular Formula C18H32N4O4

Formula Weight 372.48 g/mol

CAS No 26001-32-1

Top Ten Keywords from Google

  1. Ile-Pro-Pro
  2. Tripeptide
  3. Blood pressure
  4. Endothelial function
  5. Food sources
  6. Peptide therapy
  7. Antihypertensive
  8. ACE inhibitors
  9. Health benefits
  10. Natural compounds

Synonyms

  • IPP peptide
  • Isoleucylprolylproline

Health Benefits of this Product Ile-Pro-Pro has a number of potential health benefits due to its ability to lower blood pressure and improve endothelial function. Some of the most important health benefits of this compound include:

  1. Lowering blood pressure: Ile-Pro-Pro has been shown to help lower blood pressure in individuals with hypertension.

  2. Improving endothelial function: Ile-Pro-Pro may help improve endothelial function by increasing nitric oxide production and reducing oxidative stress.

Potential Effects The potential effects of Ile-Pro-Pro are numerous and varied. Some of the most notable effects of this compound include:

  1. Angiotensin-converting enzyme inhibition: Ile-Pro-Pro inhibits angiotensin-converting enzyme (ACE), which plays a role in regulating blood pressure.

  2. Nitric oxide production: Ile-Pro-Pro increases nitric oxide production, which helps improve endothelial function.

Product Mechanism Ile-Pro-Pro works by inhibiting angiotensin-converting enzyme (ACE), an enzyme that regulates blood pressure. By inhibiting ACE, Ile-Pro-Pro helps reduce blood pressure, making it a valuable tool in the treatment of hypertension. Additionally, Ile-Pro-Pro may help improve endothelial function by increasing nitric oxide production and reducing oxidative stress.

Safety Ile-Pro-Pro is generally considered to be safe when consumed in moderation. However, like all compounds, it can cause side effects in some people. It is important to speak with your healthcare provider before taking Ile-Pro-Pro supplements or consuming large amounts of foods rich in this compound.

Side Effects Some of the most common side effects of Ile-Pro-Pro include digestive discomfort, such as bloating, gas, and diarrhea. Other possible side effects include allergic reactions, changes in blood pressure, and interactions with certain medications. If you experience any of these side effects, it is important to contact your healthcare provider immediately.

Dosing Information The appropriate dose of Ile-Pro-Pro will vary depending on the individual and the condition being treated. It is important to follow the dosing instructions provided by your healthcare provider or the supplement manufacturer.

Conclusion In conclusion, Ile-Pro-Pro is a tripeptide composed of isoleucine, proline, and proline. It is found naturally in foods such as milk and soybeans and has been shown to have potential health benefits, such as lowering blood pressure and improving endothelial function. Its mechanism of action involves inhibiting angiotensin-converting enzyme (ACE), which regulates blood pressure. While Ile-Pro-Pro is generally considered safe, it can cause side effects in some people, and it is important to speak with your healthcare provider before taking supplements or consuming large amounts of foods rich in this compound. Despite some possible side effects, Ile-Pro-Pro is a promising compound with potential therapeutic applications in the treatment of hypertension and other cardiovascular conditions.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code